Transcatheter Aortic Valve Replacement in Patients With Reduced Ejection Fraction and Nonsevere Aortic Stenosis
Standard
Transcatheter Aortic Valve Replacement in Patients With Reduced Ejection Fraction and Nonsevere Aortic Stenosis. / Ludwig, Sebastian; Schofer, Niklas; Abdel-Wahab, Mohamed; Urena, Marina; Jean, Guillaume; Renker, Matthias; Hamm, Christian W; Thiele, Holger; Iung, Bernard; Ooms, Joris F; Wiessman, Maya; Mogensen, Nils S B; Longère, Benjamin; Perrin, Nils; Ben Ali, Walid; Coisne, Augustin; Dahl, Jordi S; Van Mieghem, Nicolas M; Kornowski, Ran; Kim, Won-Keun; Clavel, Marie-Annick.
In: CIRC-CARDIOVASC INTE, Vol. 16, No. 5, 05.2023, p. e012768.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Transcatheter Aortic Valve Replacement in Patients With Reduced Ejection Fraction and Nonsevere Aortic Stenosis
AU - Ludwig, Sebastian
AU - Schofer, Niklas
AU - Abdel-Wahab, Mohamed
AU - Urena, Marina
AU - Jean, Guillaume
AU - Renker, Matthias
AU - Hamm, Christian W
AU - Thiele, Holger
AU - Iung, Bernard
AU - Ooms, Joris F
AU - Wiessman, Maya
AU - Mogensen, Nils S B
AU - Longère, Benjamin
AU - Perrin, Nils
AU - Ben Ali, Walid
AU - Coisne, Augustin
AU - Dahl, Jordi S
AU - Van Mieghem, Nicolas M
AU - Kornowski, Ran
AU - Kim, Won-Keun
AU - Clavel, Marie-Annick
PY - 2023/5
Y1 - 2023/5
N2 - BACKGROUND: The potential benefit of transcatheter aortic valve replacement (TAVR) in patients with nonsevere aortic stenosis (AS) and heart failure is controversial. This study aimed to assess outcomes of patients with nonsevere low-gradient AS (LGAS) and reduced left ventricular ejection fraction undergoing TAVR or medical management.METHODS: Patients undergoing TAVR for LGAS and reduced left ventricular ejection fraction (<50%) were included in a multinational registry. True-severe low-gradient AS (TS-LGAS) and pseudo-severe low-gradient AS (PS-LGAS) were classified according to computed tomography-derived aortic valve calcification thresholds. A medical control group with reduced left ventricular ejection fraction and moderate AS or PS-LGAS was used (Medical-Mod). Adjusted outcomes between all groups were compared. Among patients with nonsevere AS (moderate or PS-LGAS), outcomes after TAVR and medical therapy were compared using propensity score-matching.RESULTS: A total of 706 LGAS patients undergoing TAVR (TS-LGAS, N=527; PS-LGAS, N=179) and 470 Medical-Mod patients were included. After adjustment, both TAVR groups showed superior survival compared with Medical-Mod patients (all P<0.001), while no difference was found between TS-LGAS and PS-LGAS TAVR patients (P=0.96). After propensity score-matching among patients with nonsevere AS, PS-LGAS TAVR patients showed superior 2-year overall (65.4%) and cardiovascular survival (80.4%) compared with Medical-Mod patients (48.8% and 58.5%, both P≤0.004). In a multivariable analysis including all patients with nonsevere AS, TAVR was an independent predictor of survival (hazard ratio, 0.39 [95% CI, 0.27-0.55]; P<0.0001).CONCLUSIONS: Among patients with nonsevere AS and reduced left ventricular ejection fraction, TAVR represents a major predictor of superior survival. These results reinforce the need for randomized-controlled trials comparing TAVR versus medical management in heart failure patients with nonsevere AS.REGISTRATION: URL: https://www.CLINICALTRIALS: gov; Unique identifier: NCT04914481.
AB - BACKGROUND: The potential benefit of transcatheter aortic valve replacement (TAVR) in patients with nonsevere aortic stenosis (AS) and heart failure is controversial. This study aimed to assess outcomes of patients with nonsevere low-gradient AS (LGAS) and reduced left ventricular ejection fraction undergoing TAVR or medical management.METHODS: Patients undergoing TAVR for LGAS and reduced left ventricular ejection fraction (<50%) were included in a multinational registry. True-severe low-gradient AS (TS-LGAS) and pseudo-severe low-gradient AS (PS-LGAS) were classified according to computed tomography-derived aortic valve calcification thresholds. A medical control group with reduced left ventricular ejection fraction and moderate AS or PS-LGAS was used (Medical-Mod). Adjusted outcomes between all groups were compared. Among patients with nonsevere AS (moderate or PS-LGAS), outcomes after TAVR and medical therapy were compared using propensity score-matching.RESULTS: A total of 706 LGAS patients undergoing TAVR (TS-LGAS, N=527; PS-LGAS, N=179) and 470 Medical-Mod patients were included. After adjustment, both TAVR groups showed superior survival compared with Medical-Mod patients (all P<0.001), while no difference was found between TS-LGAS and PS-LGAS TAVR patients (P=0.96). After propensity score-matching among patients with nonsevere AS, PS-LGAS TAVR patients showed superior 2-year overall (65.4%) and cardiovascular survival (80.4%) compared with Medical-Mod patients (48.8% and 58.5%, both P≤0.004). In a multivariable analysis including all patients with nonsevere AS, TAVR was an independent predictor of survival (hazard ratio, 0.39 [95% CI, 0.27-0.55]; P<0.0001).CONCLUSIONS: Among patients with nonsevere AS and reduced left ventricular ejection fraction, TAVR represents a major predictor of superior survival. These results reinforce the need for randomized-controlled trials comparing TAVR versus medical management in heart failure patients with nonsevere AS.REGISTRATION: URL: https://www.CLINICALTRIALS: gov; Unique identifier: NCT04914481.
KW - Humans
KW - Transcatheter Aortic Valve Replacement/adverse effects
KW - Stroke Volume
KW - Ventricular Function, Left
KW - Treatment Outcome
KW - Aortic Valve Stenosis/diagnostic imaging
KW - Aortic Valve/diagnostic imaging
KW - Ventricular Dysfunction, Left
KW - Heart Failure/diagnostic imaging
KW - Risk Factors
KW - Severity of Illness Index
U2 - 10.1161/CIRCINTERVENTIONS.122.012768
DO - 10.1161/CIRCINTERVENTIONS.122.012768
M3 - SCORING: Journal article
C2 - 37192310
VL - 16
SP - e012768
JO - CIRC-CARDIOVASC INTE
JF - CIRC-CARDIOVASC INTE
SN - 1941-7640
IS - 5
ER -
